Literature DB >> 31735289

Fibroblasts Fuel Immune Escape in the Tumor Microenvironment.

Emiel A De Jaeghere1, Hannelore G Denys2, Olivier De Wever3.   

Abstract

Immune escape is central to the persistence of most, if not all, solid tumors and poses a critical obstacle to successful cancer (immuno)therapy. Cancer-associated fibroblasts (CAFs) constitute the most prevalent, yet heterogeneous, component of the tumor stroma, where they 'cool down' the immune microenvironment. The central role played by CAFs, both as a physical barrier and source of immunosuppressive molecules, sets them as a target to enhance immunotherapy of cancer. We outline the current understanding of how CAFs fuel immune escape, as well as their potential clinical applications. Whether these therapeutics really have clinically significant activity remains to be seen, but the outlook is positive.
Copyright © 2019. Published by Elsevier Inc.

Entities:  

Keywords:  cancer modeling; cancer-associated fibroblasts; immune escape; immune system; immunotherapy; tumor microenvironment

Year:  2019        PMID: 31735289     DOI: 10.1016/j.trecan.2019.09.009

Source DB:  PubMed          Journal:  Trends Cancer        ISSN: 2405-8025


  34 in total

Review 1.  Key promoters of tumor hallmarks.

Authors:  Keywan Mortezaee; Jamal Majidpoor
Journal:  Int J Clin Oncol       Date:  2021-11-13       Impact factor: 3.402

2.  Three subtypes of lung cancer fibroblasts define distinct therapeutic paradigms.

Authors:  Haichuan Hu; Zofia Piotrowska; Patricia J Hare; Huidong Chen; Hillary E Mulvey; Aislinn Mayfield; Sundus Noeen; Krystina Kattermann; Max Greenberg; August Williams; Amanda K Riley; Jarad J Wilson; Ying-Qing Mao; Ruo-Pan Huang; Mandeep K Banwait; Jeffrey Ho; Giovanna S Crowther; Lida P Hariri; Rebecca S Heist; David P Kodack; Luca Pinello; Alice T Shaw; Mari Mino-Kenudson; Aaron N Hata; Lecia V Sequist; Cyril H Benes; Matthew J Niederst; Jeffrey A Engelman
Journal:  Cancer Cell       Date:  2021-10-07       Impact factor: 31.743

Review 3.  3D-bioprinted cancer-on-a-chip: level-up organotypic in vitro models.

Authors:  Maria V Monteiro; Yu Shrike Zhang; Vítor M Gaspar; João F Mano
Journal:  Trends Biotechnol       Date:  2021-09-20       Impact factor: 19.536

4.  Pembrolizumab, radiotherapy, and an immunomodulatory five-drug cocktail in pretreated patients with persistent, recurrent, or metastatic cervical or endometrial carcinoma: Results of the phase II PRIMMO study.

Authors:  Katrien Vandecasteele; Hannelore G Denys; Emiel A De Jaeghere; Sandra Tuyaerts; An M T Van Nuffel; Ann Belmans; Kris Bogaerts; Regina Baiden-Amissah; Lien Lippens; Peter Vuylsteke; Stéphanie Henry; Xuan Bich Trinh; Peter A van Dam; Sandrine Aspeslagh; Alex De Caluwé; Eline Naert; Diether Lambrechts; An Hendrix; Olivier De Wever; Koen K Van de Vijver; Frédéric Amant
Journal:  Cancer Immunol Immunother       Date:  2022-08-12       Impact factor: 6.630

Review 5.  Pancreatic ductal adenocarcinoma: tumor microenvironment and problems in the development of novel therapeutic strategies.

Authors:  Alla Kuznetsova; Olga Popova; Dmitry Panchenkov; Tatyana Dyuzheva; Alexey Ivanov
Journal:  Clin Exp Med       Date:  2022-09-09       Impact factor: 5.057

6.  Single-cell entropy network detects the activity of immune cells based on ribosomal protein genes.

Authors:  Qiqi Jin; Chunman Zuo; Haoyue Cui; Lin Li; Yiwen Yang; Hao Dai; Luonan Chen
Journal:  Comput Struct Biotechnol J       Date:  2022-06-30       Impact factor: 6.155

7.  Activated fibroblasts enhance cancer cell migration by microvesicles-mediated transfer of Galectin-1.

Authors:  Alessandra Toti; Alice Santi; Elisa Pardella; Ilaria Nesi; Richard Tomasini; Tommaso Mello; Paolo Paoli; Anna Caselli; Paolo Cirri
Journal:  J Cell Commun Signal       Date:  2021-05-22       Impact factor: 5.782

8.  Integrated Characterization of lncRNA-Immune Interactions in Prostate Cancer.

Authors:  Wei Hu; Yanru Wang; Zhixiao Fang; Wei He; Shengli Li
Journal:  Front Cell Dev Biol       Date:  2021-02-16

9.  Stromal SOX2 Upregulation Promotes Tumorigenesis through the Generation of a SFRP1/2-Expressing Cancer-Associated Fibroblast Population.

Authors:  Hiroaki Kasashima; Angeles Duran; Anxo Martinez-Ordoñez; Yuki Nakanishi; Hiroto Kinoshita; Juan F Linares; Miguel Reina-Campos; Yotaro Kudo; Antoine L'Hermitte; Masakazu Yashiro; Masaichi Ohira; Fei Bao; Daniele V F Tauriello; Eduard Batlle; Maria T Diaz-Meco; Jorge Moscat
Journal:  Dev Cell       Date:  2020-11-17       Impact factor: 12.270

10.  RHBDF1 promotes AP-1-activated endothelial-mesenchymal transition in tumor fibrotic stroma formation.

Authors:  Shan Gao; Li-Song Zhang; Lei Wang; Nan-Nan Xiao; Hui Long; Yi-Lun Yin; Yu-Meng Yang; Zhen Xi; Lu-Yuan Li; Zhi-Song Zhang
Journal:  Signal Transduct Target Ther       Date:  2021-07-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.